电话咨询
输入您的电话,即刻取得联系
返回顶部
About Gao Mai
Pharmaceuticals serve the people's livelihood; we are proud to fulfill our original aspiration
Company Profile
Gaomai Pharmaceutical was established on August 8, 2018, specializing in providing one-stop solutions in the field of skin health. With the development and industrialization of transdermal drug delivery technology as the core, it possesses a prescription reverse engineering technology platform, an industrialization process technology platform, and an in vitro evaluation technology platform. Deeply layout sales attributes and focus on light medical aesthetic drugs and medical devices.
The company currently operates under a dual-wheel drive model of CRO and MAH, serving as a production plant for strategic cooperative factories. And always adhere to the three-step strategy of high-end imitation, the combination of imitation and creation for technological upgrading, and independent innovation; We have successfully facilitated multiple varieties to obtain production approval documents for consistency evaluation.
Based on the external application technology of chemical drugs, it expands the field of external application of traditional Chinese medicine. Through mature academic promotion, online operation and OTC channel network, it deeply cultivates the skin health market and is committed to building a leading enterprise in external medicine that combines professionalism and consumer medical characteristics.
100+
R&D team members
20+
Patents
60+
Self-developed and initiated projects
7+
Enterprise honors
40+
Cooperative enterprises
Real scene of the laboratory
Development history
2018.08
Suzhou Gaomai Pharmaceutical Co., Ltd. was established
2021
From 2021 to 2023, it was consecutively recognized as a national-level technology-based small and medium-sized enterprise for three years.
In 2022, multiple strategic partners within the industry were identified
2023
Establishment of BSL2 Biosafety Laboratory
The first consistency evaluation application for Adapalene gel has been submitted.
The first cooperative development project, liprodicaine Cream, has been approved
2023.12
Multiple varieties submitted applications simultaneously
National High-tech Enterprise Certification
2024.06
The first consistency evaluation of Adaparin peroxybenzoyl gel has been submitted for application.
Become the first listed company in the field of topical medications
Development history
2018.08
Suzhou Gaomai Pharmaceutical Co., Ltd. was established
2021
From 2021 to 2023, it was consecutively recognized as a national-level technology-based small and medium-sized enterprise for three years.
In 2022, multiple strategic partners within the industry were identified
2023
Establishment of BSL2 Biosafety Laboratory
The first consistency evaluation application for Adapalene gel has been submitted.
The first cooperative development project, liprodicaine Cream, has been approved
2023.12
Multiple varieties submitted applications simultaneously
National High-tech Enterprise Certification
2024.06
The first consistency evaluation of Adaparin peroxybenzoyl gel has been submitted for application.
Become the first listed company in the field of topical medications
Cultural concept
Joint Contribution
Unite our efforts to forge ahead into a new situation
Shared Responsibility
We stand together through thick and thin and fulfill our mission
Share
Value co-creation unlocks the future
"Win-win"
Harmony and coexistence lead to a vast world
Employee Profile